← FDA DRUG APPROVALS

FDA BLA · BLA761429

OPDIVO QVANTIG

Sponsor: BRISTOL-MYERS SQUIBB

APPLICATION
BLA761429
TYPE
BLA
ORIGINAL APPROVAL
2024-12-27
LATEST ACTION
2024-12-27
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

OPDIVO QVANTIGPrescription
NIVOLUMAB 600MG, HYALURONIDASE-NVHY 10000 UNITS PER 5ML(120MG/2000UNITS PER ML) · INJECTABLE · INJECTION

Approval history

2024-12-27Type 9 - New indication submitted as distinct BLA, consolidated · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →